NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (MESO; ASX:MSB), the global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the current treatment landscape and unmet medical needs for Patients with chronic low back pain (CLBP) due to degenerative disc disease, a condition associated with localized inflammation of the disc. The webinar includes presentations from Key Opinion Leaders (KOLs) Douglas P. Beall, MD, FIPP, FSIR, DAAPM (Clinical Radiology Oklahoma) and Hyun W. Bae, MD (Spine-Center at Cedars-Sinai Medical Center).

Silviu Itescu, Chief Executive of Mesoblast, will provide an overview of the three-year results of the completed 404-patient Phase 3 randomized controlled trial of Rexlemestrocel-L in patients with CLBP due to degenerative disc disease and the regulatory path to market.

Webinar begins at 6:00 p.m. EDT, Thursday, June 16; 8:00am AEST, Friday 17 June 2022. Pre-registration is required for the webcast. Click here to access or use the following link: https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp?Y2lk=MTg2OA==

The archived webcast will be available on the Investors page of the Company’s website: www.mesoblast.com

speaker biographies

Douglas P. Beall, MD, FIPP, FSIR, DAAPM
Douglas P. Beall, MD, FIPP, FSIR, DAAPM attended medical school at Georgetown University School of Medicine in Washington, DC and completed his residency at Johns Hopkins Hospital in Baltimore, Maryland. After his residency, he was Chief of Interventional Services at Sheppard Air Force Base in Wichita Falls, Texas. He then completed a fellowship in musculoskeletal radiology at the Mayo Clinic in Rochester, Minnesota, where he trained in interventional spine techniques before returning to the US Air Force as chief of the musculoskeletal radiology department. After serving as a major in the US Air Force, Dr. Beall was Chief of Musculoskeletal Radiology and Fellowship Director at the University of Oklahoma before entering private practice as Chief of Services. In addition to his expertise in musculoskeletal imaging and interventional spinal care, Dr. Beall actively involved in teaching and research. He is Board Certified in Diagnostic Radiology, holds an Additional Fellowship in Musculoskeletal Radiology, is a Diplomate of the American Academy of Pain Management and Fellow of the Society of Interventional Radiology and Interventional Pain Practice, and is board certified by the World Institute of Pain. He is currently in private practice focused on interventional pain management and orthopedic imaging.

dr Beall has published more than 250 peer-reviewed articles, authored 6 textbooks and 75 textbook chapters, given more than 1000 invited lectures and scientific presentations, and participated in 55 clinical research studies. He currently serves as Chief of Services for Comprehensive Specialty Care in Oklahoma City, as well as Division Head of Interventional Spine Care and Director of Pain Management Fellowship Programs at the Spine Fracture Institute and Comprehensive Care Surgical Center.

Hyun W Bae, MD
Hyun W. Bae, MD is a board certified orthopedic and spine surgeon. dr Bae joined Cedars-Sinai Medical Center’s Spine Center in 2010. He is currently Professor of Surgery in the Department of Orthopedic Surgery at Cedars-Sinai Medical Center, Director of the Education and Fellowship Program.

dr Bae began his medical studies at Columbia University School of Engineering and Applied Sciences, where he graduated with a degree in biomechanics. He then completed his medical studies with cum laude

Yale University school of medicine. dr Bae completed his surgical internship at North Shore University Hospital and his orthopedic surgical residency at the Hospital for Special Surgery in New York. He completed his Spine Fellowship at Case Western Hospital in Cleveland under the direction of the late Henry H. Bohlman, MD.

1993-1994 Research Fellow in Molecular and Cellular Biology, NIH Howard Hughes Research Fellow Bethesda, MD. During this time he discovered a passion for musculoskeletal tissue engineering while working with scientists Guilak F, Setton LA, Soslowsky LJ as an undergraduate student in Dr. Van Mow collaborated.

About mesoblast
Mesoblast is a global leader in the development of allogeneic (ready-to-use) cellular drugs to treat serious and life-threatening inflammatory diseases. The Company has leveraged its proprietary mesenchymal lineage cell therapy platform to establish a broad portfolio of late-stage product candidates that address severe inflammation by releasing anti-inflammatory factors that counteract and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio, protected in all major markets until at least 2041. The company’s proprietary manufacturing processes deliver cryopreserved, commercially available cellular drugs on an industrial scale. These cell therapies with defined pharmaceutical release criteria should be easily accessible to patients worldwide.

Mesoblast is developing product candidates for multiple indications based on its Remestemcel-L and Rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft-versus-host disease, bioresistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees and the Company has established commercial partnerships in Europe and China for certain Phase 3 facilities.

Mesoblast has offices in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and Nasdaq (MESO, finance). For more information, visit www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements
This press release contains forward-looking statements, which relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements to differ materially from future results, activities, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from those anticipated in these forward-looking statements, and the differences could be material and adverse. Forward-looking statements include, but are not limited to, statements regarding: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies and research and development programs; Mesoblast’s ability to enroll and successfully complete product candidates in clinical trials, including multinational clinical trials; Mesoblast’s ability to expand its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals (including BLA re-submission), manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s product candidates, if approved; regulatory or public perceptions and market acceptance related to the use of stem cell-based therapies; the possibility that Mesoblast’s product candidates, if approved, may be withdrawn from the market due to adverse events or patient deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property in its product candidates and Mesoblast’s ability to successfully defend it in cases of alleged infringement; the level of intellectual property protection that Mesoblast can establish and maintain for its product candidates and technologies; Estimates of Mesoblast’s expenses, future revenues, capital requirements and its need for additional funding; financial performance of Mesoblast; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release along with our risk factors in our most recent SEC filings or on our website. Uncertainties and risks that could cause Mesoblast’s actual results, performance or achievements to differ materially from those expressed or implied by such statements and accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Release approved by Chief Executive.

For more information, please contact:

Mesoblast Limited.png>